Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761680 | 1.00 | PEPD (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL7761683 | 1.00 | PEPD (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL8411453 | 1.00 | PEPD (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL8411456 | 1.00 | PEPD (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL12427230 | 0.97 | PEPD (0.54) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL7815469 | 0.95 | EPHX1 (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL1258973 | 0.95 | EPHX1 (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL7818915 | 0.95 | EPHX1 (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL7815466 | 0.95 | EPHX1 (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 | |
| SCHEMBL7818913 | 0.95 | EPHX1 (0.56) | PEPDEPHX1ALDH1A1LMNAGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216063207-U | Cyclization reaction kettle for synthesizing 1, 2-cyclopentanedicarboximide | 安徽金鼎医药股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-112624958-A | Synthetic method of medical intermediate 1, 2-cyclopentadienimide | 安徽金鼎医药股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-2882740-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | disclosed |
| EP-1093460-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000002906-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| US-5962724-A | FROM THE CORRESPONDING MESODICARBOXYLIC ACID ANHYDRIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | disclosed |
| EP-0932598-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998016502-A1 | ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-4196291-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1980-04-01 | — | — | US | disclosed |
| US-4141978-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-02-27 | — | — | US | disclosed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4001411-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018422-A1 | Dolastatin 15 derivatives | SLCO2B1, SLCO2A1, DDOST | PEPD 543/4885EPHX1 1775/4885ALDH1A1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.